Ireland · Elsevier Ireland Ltd

workspace_premium Q2 — Medicine (miscellaneous) lock_open Open Access

Atherosclerosis Supplements

Atherosclerosis Supplements is a journal indexed in SJR in Medicine (miscellaneous) and Internal Medicine with an H index of 50. It has a best quartile of Q2. It is published in English.

ISSN: 1567-5688

Publisher: Elsevier Ireland Ltd

Category: Medicine (miscellaneous)

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

NPD Q2

H-index 50

Acceptance rate pie_chart

30% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Open Access

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

SJR Impact

—

H-index

Docs (year)

Docs 3y

Total refs

280

Cites 3y

195

Citable 3y

Cites/Doc 2y

1,24

Ref/Doc

2545.0

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

C-REACTIVE PROTEIN EXERTS POTENT ANGIOGENIC EFFECTS ON HUMAN VASCULAR ENDOTHELIAL CELLS

Unpremeditated tribute to Akira Endo

Familial hypercholesterolemia in Brazil

Exercise training accelerates the chylomicron metabolism

Endothelial function in the post-prandial state

Effects of fosinopril on lipid profile and Lp(a) in normotensive patients with type 2 diabetes and microalbuminuria

EFFECTS OF AN INHIBITOR OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE ON SERUM LIPOPROTEINS AND UBIQUINONE-10 LEVELS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA

Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography

Does intracoronary intervention effect the duration of platelet aggregation in-vitro?

Determination to treat patients with FH-how fundamental techniques in medical consultation saved the day

Congratulatory Address

COMPETITIVE INHIBITION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE BY ML-236A AND ML-236B FUNGAL METABOLITES, HAVING HYPOCHOLESTEROLEMIC ACTIVITY

SHOW MORE ARTICLES

Coadministration of ezetimibe and fenofibrate leads to favorable effects on Apo CIII and LDL subfractions

580 PREVALENCE OF DIABETES AND OF IMPAIRED GLUCOSE TOLERANCE IN PATIENTS WITH ATHEROSCLEROSIS: THE IMPORTANCE OF THE INVOLVED ARTERIAL BEDS

Body mass index and cardiovascular risk factors in patients with diabetes mellitus type 2

Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events

Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase

Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis

Apolipoprotein A-IV polymorphisms: frequency and effects on lipids and apolipoproteins among individuals in Northwestern Greece

Angiogenesis and endothelial damage in acute myocardial infarction: an acute or chronic process?

An increased inflammatory activation is related to the metabolic syndrome in 58-year old men (air-study)

ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease

A unique cholesterol-lowering agent that no one had ever had before

A tribute to Akira Endo, discoverer of a "Penicillin" for cholesterol

FAQs

SJR is not available (NPD) for Atherosclerosis Supplements in the CountryOfPapers database.

Immediate OA APC is not available (NPD). Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Atherosclerosis Supplements is 30%.

Atherosclerosis Supplements

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Atherosclerosis Supplements?

What is the APC / publication cost?

What is the acceptance rate?